Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - September 2013


Hands-on Tablet Development, including the principles of Pre-Formulation, Formulation and Process Development

11 Sep 2013 - 13 Sep 2013 - London, UK



Bookmark and Share


This unique 3 day course is designed to integrate the key elements of tablet development with hands-on, practical experience in a small scale, lab scale test facility. Each day will consist of lectures on aspects of tablet development, followed by linked sessions in which participants take part in related experimental work.The course enables attendees to apply the theory learnt in the taught sessions, and also to directly observe the effect of formulation on product properties, and relate the theory to the practice of Quality by Design (QbD).

Learning outcomes:

  • Understanding of the relationship between Quality by Design, drug substance properties, formulation and process development
  • Practical experience of small scale tablet manufacture with direct knowledge of the relationship between formulation properties and tablet compressibility
  • Understanding of the roles of critical quality attributes, critical process parameters, and product control strategy in the application of the principles of QbD to formulation development

Who Should Attend?

  • Newcomers to tablet formulation development and manufacturing
  • Production operators who need a better understanding of their products and how they have been developed
  • Analytical and QC staff who would benefit from understanding the tablet development and production process
  • Experienced personnel in one area of product development who need a broader overview
  • Project team members needing a broader insight into formulation development including preclinical, clinical, and project management representatives
  • Regulatory staff who would benefit from brief practical experience of the processes for which they are compiling dossiers
  • Regulatory agency staff requiring practical experience

Course Programme

Day 1

Theme

  • Quality by Design (QbD) - ICH Q8-10
  • Material properties and their impact on processing
  • The role of excipients Course Programme

8.30am Registration and coffee/tea

9.00am Welcome. Introductions. Plan for the day. Learning objectives for course

9.15am Introduction to Quality by Design - a new pharmaceutical manufacturing system. Regulatory guidance.

10.45am Coffee break

11.00am Drug substance properties and their impact on formulation development.

Part 1 - physico-chemical properties

12.45pm Lunch

1.45pm Drug substance properties and their impact on formulation development.

Part 1 - physico-chemical properties

3.00pm Tea break

3.15pm Practical - impact of material properties on bulk powder behaviour

  • Flow
  • Bulk density
  • Compressibility
  • Particle size and shape

4.45pm Wrap up

5.00pm Close

Day 2

Theme

  • Formulating good products

9.00am Consolidation. Plan for day. Learning objectives for day

9.15am Approaches to formulation development using QbD principles. Manufacturing Process selection - applicability of wet granulation/roller compaction/direct compression. Unit processes 1 - blending.

10.30am Coffee break

10.45am Unit processes 2 - granulation and drying. Factors affecting granulation and drying behaviour. Critical Process Parameters for these processes. Impact of powder properties on manufacturing behaviour

12.15pm Powder and granule characterisation - advanced techniques. Porosity, compressibility, surface area

12.45pm Lunch

1.30pm Granulation and drying practical

3.00pm Tea break

3.15pm Lubrication and compression practical

4.45pm Wrap up

5.00pm Close

Day 3

Theme

  • Process development and validation

9.00am Consolidation. Plan for day. Learning objectives for day

9.15am Principles of process development. FDA Process Validation Guidance 2011 and the impact of QbD

10.30am Coffee

10.45am Identifiying Critical Process Parameters and Critical Quality Attributes

  • Blending
  • Granulation
  • Drying
  • Lubrication
  • Compression

12.45pm Lunch

1.45pm Practical - Direct compression products

Impact of excipient selection, grades, and processing on critical quality attributes

  • Compressibility
  • Friability
  • Content Uniformity
  • Disintegration

4.00pm Closing session with tea

5.00pm Depart



Further information
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!